Mescaline half-life
A modern placebo-controlled study measured mescaline for 30 hours and reported an approximately 3.5-hour plasma elimination half-life.
Every curve begins at 100%. No dose or measured body concentration is assumed.
X-axis: elapsed time. Y-axis: modeled percentage of the relative starting point remaining. This is a mathematical visualization, not a personal concentration estimate.
Mescaline: evidence and interpretation notes
The pharmacokinetic question
A modern placebo-controlled study measured mescaline for 30 hours and reported an approximately 3.5-hour plasma elimination half-life. Subjective effects lasted much longer and increased with dose, making this a particularly clear half-life-versus-duration example.
The calculator follows Parent mescaline in plasma with a 3.5-hour half-life. That simplification is useful for curve shape and comparison, but it is not an individualized pharmacokinetic estimate.
Mescaline may have subjective effects that diverge from parent-compound plasma half-life. The curve is best used to compare pharmacokinetic persistence, not experience length, intensity, or psychological risk.
What each source contributes
- PubChem: Mescaline. This identity record confirms names and compound identity and does not supply a human half-life.
- Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. This human pharmacokinetic record adds measured route, analyte, and population context and does not become a universal result.
For Mescaline, the numerical model is tied most closely to Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects. As a human pharmacokinetic record, it adds measured route, analyte, and population context; it does not become a universal result.
Why there is no range on the chart
This profile plots 3.5 hours for Parent mescaline in plasma without adding an unsourced high-low band. A single supported center is more honest than manufacturing a range from unrelated routes, populations, or formulations.
InterpretationReading the curve and its category context
Reading this curve
HalfLifeDB uses 3.5 h as a representative input for Parent mescaline in plasma. In the simplified model, about 0.9% remains after 24 hours and about 3% remains after five half-lives, or roughly 17.5 h.
This is a short curve. The modeled amount changes noticeably over the same day, while effects, metabolites, and safety questions can still follow a different timeline. The curve is relative: it does not estimate a person's measured concentration, effects, impairment, or time to clearance.
psychedelic context
Psychedelic duration is shaped by pharmacodynamics as well as pharmacokinetics, so subjective effects may not track a simple elimination curve.
- The curve does not predict psychological effects or functional safety.
- Metabolites and downstream receptor activity are not separately modeled.
- Published estimates may come from small or specialized study populations.
ComparisonTimeline checkpoints and nearby profiles
Mescaline timeline checkpoints
| Elapsed time | Modeled remaining | Reading note |
|---|---|---|
| 6 h | 30.5% | Long-tail portion of the model |
| 12 h | 9.29% | Low modeled remainder, not a clearance guarantee |
| 24 h | 0.86% | Low modeled remainder, not a clearance guarantee |
| 2.0 days | 0.01% | Low modeled remainder, not a clearance guarantee |
| 3.0 days | 0.00% | Low modeled remainder, not a clearance guarantee |
Nearby profiles by half-life
These entries sit near Mescaline within the psychedelic group when sorted by representative half-life. That makes them curve comparisons, not statements about equal potency, effects, or risk.
- LSD (3.6 h)
- Psilocybin (3 h)
- DMT (10 min)
EvidencePharmacokinetic inputs and source trail
Pharmacokinetics at a glance
| Representative half-life | 3.5 h |
|---|---|
| Modeled analyte or phase | Parent mescaline in plasma |
| Curve type | Normalized, first-order decline |
Selection note: A modern placebo-controlled study measured mescaline for 30 hours and reported an approximately 3.5-hour plasma elimination half-life. Subjective effects lasted much longer and increased with dose, making this a particularly clear half-life-versus-duration example.
Sources and evidence context
A linked record is not automatically proof of the displayed value. Study, labeling, review, and compound identity sources serve different purposes; notes below identify limitations when they are known.
- Identity record PubChem Compound Summary: Mescaline.Compound identity and naming record. It supplies chemistry context, not independent numerical support for the model.
- Research abstract PubMed: Acute dose-dependent effects of mescaline in a double-blind placebo-controlled study in healthy subjects.Direct pharmacokinetic context. Population, route, formulation, analyte, and sampling duration still determine how broadly the result can be applied.
BoundariesWhat this page cannot answer and where to continue
What this page does not answer
- It does not estimate impairment, intoxication, or fitness to drive.
- It does not predict urine, blood, saliva, or hair test results.
- It does not model repeated exposure, tolerance, withdrawal, or interactions.
- It does not replace clinician, pharmacist, toxicologist, or emergency guidance.
Continue with context
- All substance profiles
- Browse the psychedelic group
- Compare this curve
- Clearance and volume of distribution
- Bioavailability, route, and formulation
- Active metabolites and parent compounds
- First-order vs nonlinear kinetics
- Detection windows vs half-life
- Reading labels and source quality
Read the medical disclaimer, methodology, and research standards before using the model for comparison.